Compound Planning Inc. Purchases 1,373 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Compound Planning Inc. increased its stake in Thermo Fisher Scientific by 52.4%, acquiring an additional 1,373 shares, bringing its total holdings to 3,992 shares valued at approximately $1,987,000.
• Several hedge funds, including Revolve Wealth Partners and Port Capital, have also increased their positions in Thermo Fisher Scientific, with institutional investors owning 89.23% of the stock.
• The company recently reported earnings of $5.36 per share, exceeding analysts' estimates, and announced a quarterly dividend of $0.43 per share to be paid on October 15th.

Compound Planning Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,992 shares of the medical research company's stock after purchasing an additional 1,373 shares during the period. Compound Planning Inc.'s holdings in Thermo Fisher Scientific were worth $1,987,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. GAMMA Investing LLC boosted its position in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at about $532,360,000. Kovitz Investment Group Partners LLC boosted its position in Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after buying an additional 858,193 shares during the last quarter. Farallon Capital Management LLC boosted its position in Thermo Fisher Scientific by 73.8% in the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after buying an additional 523,800 shares during the last quarter. Finally, Sarasin & Partners LLP purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at about $242,991,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.0%

Thermo Fisher Scientific stock traded down $0.01 during midday trading on Wednesday, reaching $488.47. The stock had a trading volume of 1,284,766 shares, compared to its average volume of 2,459,217. The firm's fifty day simple moving average is $446.71 and its two-hundred day simple moving average is $455.47. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $184.45 billion, a price-to-earnings ratio of 28.25, a PEG ratio of 2.62 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock valued at $13,603,438 in the last three months. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TMO. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Argus cut their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, Barclays lifted their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.